Analysis on the effect and safety of compound Biejiaruangan tablets combined with entecavir on the treatment of viral hepatitis B cirrhosis
10.3969/j.issn.1005-1678.2017.06.045
- VernacularTitle:复方鳖甲软肝片联合恩替卡韦治疗乙肝后肝硬化效果及安全性分析
- Author:
Hui SHAO
;
Jingyan CHEN
;
Huazhong CHEN
- Keywords:
compound Biejiaruangan tablets;
entecavir;
viral hepatitis B cirrhosis;
safety
- From:
Chinese Journal of Biochemical Pharmaceutics
2017;37(6):122-123
- CountryChina
- Language:Chinese
-
Abstract:
Objective To study the effect and safety of compound Biejiaruangan tablets combined with entecavir on the treatment of viral hepatitis B cirrhosis.Methods100 cases with hepatitis B cirrhosis in Zhejiang Taizhou hospital from June 2014 to December 2016 were selected as the research object in this study which were randomly divided into the control group and the experimental group 50 cases in each group.The control group were given entecavir, the experimental group were given compound Biejiaruangan tablets combined with entecavir.The clinical effect and the adverse reaction in the two groups were compared.ResultsThe effective rate was 90.0% in the experimental group, which was significantly higher than 72.0% in the control group(P<0.05).There were 2 patients vomiting in the experimental group, the adverse reaction rate was 4.0%.There were 9 cases of vomiting and headache in the control group, the adverse reaction rate was 18.0%.T,he adverse reaction rate(in the experimental group was significantly lower than that in the control group(P<0.05).ConclusionThe clinical effect of compound Biejiaruangan tablets combined with entecavir on the treatment of viral hepatitis B cirrhosis is better, which can reduce the rate of adverse reactions in a certain extent, is high safety, and worth popularizing.
